Earnings Call · Q2 FY2026·2026-07-30

Q2 26EPS +9.14%·Rev n/aQ1 26EPS +5.59%·Rev n/aQ4 25EPS +5.13%·Rev n/aQ3 25EPS +6.32%·Rev n/a⚠ consensus missing

AGIOS PHARMACEUTICALS, INC. AGIO

Morgan Sanford — Head of Investor Relations, RGO's Pharmaceuticals

Brian Goff — Chief Executive Officer

Cecilia Jones — Chief Financial Officer

Sveta Milanova — Chief Commercial Officer

Dr. Sarah Gheuens — Chief Medical Officer & Head of Research and Development

−6.5%1d on move date3d−12.8%5d−9.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AGIO calls or request research access.

More AGIO calls Browse calls Request research access